Advertisement
Research ArticleArticle

CHARACTERIZATION OF TRANSPORT PROTEIN EXPRESSION IN MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN (MRP) 2-DEFICIENT RATS

Brendan M. Johnson, Peijin Zhang, John D. Schuetz and Kim L. R. Brouwer
Drug Metabolism and Disposition April 2006, 34 (4) 556-562; DOI: https://doi.org/10.1124/dmd.105.005793

Abstract

Multidrug resistance-associated protein (Mrp) 2-deficient transport-deficient (TR–) rats, together with their transport-competent Wistar counterparts (wild type), have been used to examine the contribution of Mrp2 to drug disposition. However, little is known about potential variation in expression of other transport proteins between TR– and wild-type rats or whether these differences are tissue-specific. Sections of liver, kidney, brain, duodenum, jejunum, ileum, and colon were obtained from male TR– and wild-type Wistar rats. Samples were homogenized in protease inhibitor cocktail and ultracentrifuged at 100,000g for 30 min to obtain membrane fractions. Mrp2, Mrp3, Mrp4, P-glycoprotein, sodium-dependent taurocholate cotransporting polypeptide, organic anion transporting polypeptides 1a1 and 1a4, bile salt export pump, breast cancer resistance protein, ileal bile acid transporter, UDP-glucuronosyl transferase (UGT1a), glyceraldehyde-3-phosphate dehydrogenase, and β-actin protein expression were determined by Western blot. Mrp3 was significantly up-regulated in the liver (∼6-fold) and kidney (∼3.5-fold) of TR– rats compared with wild-type controls. Likewise, the expression of UGT1a enzymes was increased in the liver and kidney of TR– rats by ∼3.5- and ∼5.5-fold, respectively. Interestingly, Mrp3 expression was down-regulated in the small intestine of TR– rats, but expression was similar to wild type in the colon. Mrp4 was expressed to varying extents along the intestine. Expression of some transport proteins and UGT1a enzymes differ significantly between TR– and wild-type rats. Therefore, altered drug disposition in TR– rats must be interpreted cautiously because up- or down-regulation of other transport proteins may play compensatory roles in the presence of Mrp2 deficiency.

Multidrug resistance-associated protein (Mrp) 2 is the primary transport protein mediating excretion of organic anions, including endogenous and exogenous drug conjugates, across canalicular membranes from the hepatocytes into bile. Mrp2 also is expressed significantly on the brush-border membrane of the small intestine and proximal tubule of the kidney and therefore plays an important role in drug disposition (Borst et al., 1999). Transport-deficient (TR–) rats, naturally occurring mutants of the Wistar rat that are Mrp2-deficient (Jansen et al., 1985; Paulusma et al., 1996), have been used to elucidate the role of Mrp2 in drug disposition (Dietrich et al., 2001; Xiong et al., 2002; Chen et al., 2003a; Potschka et al., 2003). A similar mutation also exists in the Sprague-Dawley strain of rats, where the Mrp2-deficient mutant is referred to as Eisai hyperbilirubinemic rats, or EHBRs (Hirohashi et al., 1998).

TR– and EHBR rats provide an animal model for human Mrp2 deficiency, Dubin-Johnson syndrome, a condition characterized by mild chronic conjugated hyperbilirubinemia (Dubin and Johnson, 1954; Kartenbeck et al., 1996). Mrp2-deficient rats also exhibit elevated serum bile acid concentrations, alterations in bile composition, and reduced bile flow (Jansen et al., 1985). A compensatory hepatic basolateral organic anion transport mechanism, Mrp3, is induced in TR– rats, EHBRs, and in patients with Dubin-Johnson syndrome (König et al., 1999; Ortiz et al., 1999; Akita et al., 2001). Recently, Mrp3 induction on the basolateral membrane of renal proximal tubular cells also was observed in EHBRs (Kuroda et al., 2004). In addition, Kuroda et al. (2004) demonstrated that hepatic organic anion transporting polypeptide (Oatp) 1a1 and 1a4 protein levels were reduced by ∼50% in EHBRs. An increase in bilirubin glucuronidation and cytochrome P450 CYP 2a1 activity has been noted in EHBRs, whereas CYP 2b1/2 and 3a1/2 isoforms appear to be decreased and CYP 1a2, 2d, and 2e1 remain equivalent (Ohmori et al., 1991; Jäger et al., 1998). Jäger et al. (1997) reported that UGT activity was equivalent between TR– and wild-type rat livers. These observations demonstrate that tissues other than the liver and other transport proteins (such as those responsible for bile acid transport) and enzymes may be altered in Mrp2-deficient animals and humans.

Therefore the objective of the current study was to characterize expression of several key transport proteins of endogenous and exogenous compounds in the liver, kidney, brain, and intestine of TR– and wild-type Wistar rats. The transport proteins examined included those primarily involved in the transport of organic anions [Mrp2, Mrp3, and Mrp4; Oatp1a1 and Oatp1a4; and breast cancer resistance protein (Bcrp)], organic cations [P-glycoprotein (P-gp)], and bile salts [sodium-dependent taurocholate cotransporting polypeptide (Ntcp); bile salt export pump (Bsep); and ileal bile acid transporter (Ibat)]. More detailed information on the structure and function of these transport proteins in various tissues can be found in recent reviews (Kim, 2003; Trauner and Boyer, 2003; Chan et al., 2004; Chandra and Brouwer, 2004; Kushura and Sugiyama, 2004; Lee and Kim, 2004; Leslie et al., 2005). Altered expression of UGT1a in several tissues also was examined as a function of Mrp2 deficiency.

Materials and Methods

Materials and Antibodies. Phenylmethanesulfonyl fluoride (PMSF), iodoacetamide, Tween 20, and β-mercaptoethanol were obtained from Sigma-Aldrich (St. Louis, MO). Complete Protease Inhibitor Cocktail was purchased from Roche Diagnostics (Indianapolis, IN), and molecular weight marker (SeeBlue Plus2) was obtained from Invitrogen (Carlsbad, CA). Primary antibodies were obtained from the following commercial sources: P-gp (Ab-1) and breast cancer resistance protein (BCRP; Ab-1 from clone BXP-21) were obtained from Calbiochem (San Diego, CA), Mrp2 (M2-III-6) was from Alexis Biochemicals (San Diego, CA), Oatp 1a4 (AB3572P) and β-actin (MAB1501R) were from Chemicon International (Temecula, CA), UDP-glucuronosyl transferase (UGT) 1a (WB-UGT1A) was from BD Gentest (Woburn, MA), and glyceraldehyde-3-phosphate dehydrogenase (6C5) was from Abcam (Cambridge, MA). Primary antibodies to Oatp1a1 (K10), Ntcp (K4), and Bsep (K12) were generously provided by Dr. Peter Meier and Dr. Bruno Stieger (University Hospital, University of Zürich, Zürich, Switzerland). Primary antibodies to Mrp3 and Ibat were kind gifts from Dr. Yuichi Sugiyama (University of Tokyo, Tokyo, Japan) and Dr. Paul Dawson (Wake Forest University Baptist Medical Center, Winston-Salem, NC), respectively. The primary antibody to MRP4 is described in Leggas et al. (2004). All other chemicals were readily available from commercial sources and were of analytical grade or higher. Water was obtained from a Barnstead NANOpure Infinity water purification system (Dubuque, IA).

Tissue Procurement and Sample Preparation. All animal procedures were approved by the Institutional Animal Care and Use Committee (University of North Carolina at Chapel Hill). Male wild-type Wistar rats (275–325 g) were obtained from Charles River Laboratories, Inc. (Wilmington, MA) and male TR– Wistar rats (275–325 g; in-house breeding colony) were originally obtained from Dr. Mary Vore (University of Kentucky, Lexington, KY). Rats were anesthetized with ketamine and xylazine (60 and 12 mg/kg, respectively) by intraperitoneal injection, and after midline incision, the portal vein was isolated and cannulated. The liver was perfused at 30 ml/min with filtered (0.45 μm) ice-cold 0.9% NaCl until the liver lobes were devoid of blood. The liver was then removed and immediately immersed in liquid nitrogen. The kidneys were removed and the outer capsule discarded, the rat was decapitated, and the whole brain was isolated. Both the brain and kidneys were placed immediately in liquid nitrogen once they were removed.

Intestinal tissue samples were obtained from separate rats due to the observed instability of transport proteins obtained from the upper regions of the rat intestine. Rats were anesthetized as described above, and the whole small intestine from the pylorus to the ileocecal junction was removed. The intestine was sectioned into duodenum (uppermost 10 cm), jejunum (a 10-cm section starting approximately 25 cm from the pylorus), and terminal ileum (a 10-cm section immediately proximal to the ileocecal junction). The lumen of each section was flushed with freshly prepared 1 mM PMSF in 0.9% NaCl before placement in a tube of the same solution. The colon was removed, hard fecal matter was removed by gentle rolling, and the lumen was flushed with PMSF solution and placed in a tube of the same solution. The four intestinal segments were everted, and mucosal scrapings (∼400 mg of tissue per intestinal segment) were obtained using a glass slide and frozen in liquid nitrogen.

Samples (300–400 mg of tissue) of liver, kidney, brain, and scrapings from the duodenum, jejunum, ileum, and colon were thawed in a polypropylene tube under 2 ml of 1× Complete Protease Inhibitor cocktail in Tris-HCl (0.1 M, pH 7.4). Samples were homogenized on ice for two 30-s periods at 30,000 rpm (Tissue-Tearor; Biospec Products Inc., Racine, WI) and then sonicated for 30 s using a probe Sonic Dismembrator (model 100; Fisher Scientific, Pittsburgh, PA). Samples were centrifuged at 1500g at 4°C for 10 min, and the supernatant was transferred to an ultracentrifuge tube and centrifuged at 100,000g (XL-80, Beckman Coulter, Fullerton, CA). The supernatant was discarded, and the pellet was resuspended in 200 μl of Protease Inhibitor Cocktail solution by homogenization and sonication (described above) and stored at –80°C until Western blot analysis.

Western Blot Procedure. Homogenates were suitably diluted to ∼5 mg/ml total protein using a bicinchoninic acid protein assay method as per manufacturer's instructions (Pierce, Rockford, IL). Dilute homogenates were reassayed, and samples were prepared for Western blot as per manufacturer's instructions (Invitrogen) at a concentration of 50 μg/30 μl, except for samples from the colon, which were prepared at 25 μg/30 μl. Samples prepared specifically for analysis of Ibat were diluted 1:3 with an iodoacetamide solution [1 M iodoacetamide, 500 mM Tris (pH 8.7), 10% glycerol, and 2.5% sodium dodecyl sulfate (SDS)] and incubated for 30 min to minimize disulfide bond reformation and maintain Ibat in its monomeric form. Molecular weight marker was loaded in the first lane of every gel. Proteins were separated using 4 to 12% bis-Tris polyacrylamide gel electrophoresis under denaturing conditions at 150 V for 120 min and then transferred to polyvinylidene fluoride membranes (Immobilon-P; Millipore, Bedford, MA) at 30 V for 90 min as per manufacturer's instructions (Invitrogen). Membranes were blocked with 5% skim milk powder (Bio-Rad, Hercules, CA) in Tris-buffered saline (pH 7.4) with 0.3% Tween 20 (TBS-T) for 30 min at room temperature. TBS-T contained 0.1% Tween 20 for blots from intestinal segments.

Membranes were incubated with primary antibody solution (1:1000–2000 in TBS-T) for 2 h, rinsed three times for 10 min each in TBS-T, incubated in an appropriate (anti-rabbit or anti-mouse) horseradish peroxidase-conjugated secondary antibody (1:3000–10,000 in TBS-T) for 2 h, and again rinsed three times for 10 min each in TBS-T. Bands were visualized using enhanced chemiluminescence reagents (SuperSignal West Dura; Pierce) and a VersaDoc instrument (Bio-Rad).

Membranes commonly were stripped of primary and secondary antibodies, allowing reprobing of the same membrane, by incubation in a solution of β-mercaptoethanol (0.1 M), SDS (70 mM), and Tris-HCl (62 mM) at pH 6.8 for 30 to 40 min at 70°C. After stripping, membranes were rinsed in TBS-T and reblocked in 5% skim milk powder as described above.

Immunohistochemistry. Intestinal tissues collected for immunohistochemical localization of Mrp4 were obtained as described above. Small segments of duodenum, jejunum, ileum, and colon were everted, fixed in 4% paraformaldehyde in phosphate-buffered saline for 24 h, rinsed in purified water, and placed in 70% ethanol. Segments were embedded in paraffin and sectioned. Immunohistochemical staining was performed essentially as described previously (Assem et al., 2004). Briefly, deparaffinized slides were treated with 3% hydrogen peroxide in water for 5 min. Slides were then incubated for 30 min at room temperature with Mrp4 antibody diluted in 1% bovine serum albumin, washed three times with phosphate-buffered saline/Tween 20 (0.05%), and incubated with a polymer-labeled anti-rabbit secondary antibody (DakoCytomation, Carpinteria, CA). Slides were counterstained with Mayer's Hematoxylin (Sigma-Aldrich).

Data and Statistical Analysis. Integrated optical densities for bands of interest were determined using Quantity One software (Bio-Rad) and were normalized to β-actin (or glyceraldehyde-3-phosphate dehydrogenase when blotting for Ibat) determined from the same membrane. Normalized data from n = 3 wild-type and TR– rats were compared using the Student's t test at an α = 0.05 level of significance. All plots illustrate the mean and standard deviation from three wild-type and three TR– rats.

Fig. 1.
Fig. 1.

Western blots of liver (A) and kidney (B) homogenates from wild-type (WT) and TR– rats. Blots were prepared as described under Materials and Methods from three separate wild-type and TR– rats and were loaded with 50 μg of total protein per lane. In panel B, liver samples from a Wistar and TR– rat are included for reference. Approximate molecular weights (MW) are shown, and the semiquantitative assessment of blots is plotted in Fig. 2.

Results

Liver. Western blots prepared from wild-type and Mrp2-deficent TR– rat liver homogenates (n = 3) are shown in Fig. 1. Bands of interest were quantified using integrated optical density and normalized to β-actin (Fig. 2). Mrp3 protein expression was significantly higher (∼6-fold, P < 0.01) in TR– rats compared with wild type. This increase was similar to that described previously in EHBRs (Ogawa et al., 2000; Akita et al., 2001). Interestingly, expression of members of the UGT1a family was increased ∼3.5-fold in TR– rats compared with wild type. No other transport proteins studied were significantly different between wild-type and TR– rats; however, Ntcp was reduced by almost 60% in TR– rat livers (P = 0.06). Although Bsep expression also appeared to be reduced in TR– rat livers (Fig. 1), when the data were normalized to β-actin, only a 30% reduction in Bsep expression was noted (P > 0.3).

Kidney. Representative Western blots of Mrp3 and UGT1a expression in wild-type and TR– rat kidney homogenates are shown in Fig. 1. Expression of both Mrp3 and UGT1a was significantly increased in TR– rat kidney when compared with wild type. Densitometric analysis for this blot and others (data not shown) are shown in Fig. 2B. Mrp3 and UGT1a expression were ∼3.5- and ∼5.5-fold higher, respectively, in kidneys from TR– compared with wild-type rats (P < 0.001). The expression of other transport proteins examined did not differ significantly between wild-type and TR– rat kidneys.

Fig. 2.
Fig. 2.

Results of integrated optical density analyses of Western blots prepared from liver (A), kidney (B), and brain (C) homogenates from wild-type (solid bars) and TR– (open bars) rats. All data were normalized to β-actin probed on the same blot as the respective protein. Bars represent the mean and standard deviation from n = 3 preparations; the absence of a bar represents no detectable expression. Statistically significant differences between wild-type and TR– rats are indicated (*, P < 0.01).

Brain. Densitometric analysis of Western blots (data not shown) prepared from Wistar and TR– whole rat brain homogenates are plotted in Fig. 2C. No significant differences in transport protein expression between Wistar control and TR– rat brains were noted. Although Bcrp protein expression in rat brain capillary fractions was reported recently (Hori et al., 2004), a signal only slightly stronger than background staining was detected using the current antibody with whole-brain homogenate.

Intestine. A Western blot of mucosal scrapings from intestinal segments of a representative Wistar and TR– rat is shown in Fig. 3A. Mrp2 expression in Wistar control rats decreased along the length of the small intestine, and no detectable expression of Mrp2 was found in the colon. Conversely, Mrp3 expression appeared to increase distally, with high (relative) expression in the colon. Interestingly, Mrp3 expression was decreased in the small intestine of TR– rats when compared with Wistar controls. These results were confirmed from blots of n = 3 samples each from Wistar control and TR– rats (data plotted in Fig. 3B), where Mrp3 expression was decreased by 55 (P > 0.05), 81 (P < 0.05), and 71% (P < 0.05) in the duodenum, jejunum, and ileum, respectively, in TR– compared with Wistar control rats. In the colon, Mrp3 and Mrp4 expression was relatively high (Fig. 3A), with no significant difference between wild-type and TR– rats detected (Fig. 3B). Mrp4 expression was low in the jejunum and ileum, with slightly higher expression in the duodenum, where Mrp4 appeared as a double band with approximate molecular weights of 160 and 170 kDa. P-gp also appeared as a double band in the ileum, and expression along the gastrointestinal tract was in the order colon ≈ ileum > jejunum > duodenum (Fig. 3A), consistent with previous reports (Brady et al., 2002). No significant difference in P-gp expression was observed between wild-type and TR– rats (Fig. 3B). Ibat expression in the terminal ileum also was assessed (blot not shown); expression was almost 2-fold higher in TR– rats when compared with Wistar controls (Fig. 3B); however, this difference was not statistically significant (P = 0.057). Expression of UGT1a was similar in all sections of the intestine, and no significant differences in expression were observed between wild-type and TR– rats (Fig. 3B).

Fig. 3.
Fig. 3.

A, Western blot of mucosal scrapings prepared from intestinal segments of representative wild-type (WT) and TR– rats. Blot was prepared as described under Materials and Methods, and gels were loaded with 50 μg of total protein per lane with the exception of colon samples, which were loaded with 25 μg per lane. A wild-type liver sample is included in the last lane for reference (50 μg of total protein). Approximate molecular weights (MW) are shown. B, integrated optical density analyses of Western blots prepared from mucosal scrapings of duodenum (i), jejunum (ii), ileum (iii), and colon (iv) from wild-type (solid bars) and TR– (open bars) rats. All data were normalized to β-actin probed on the same blot as the respective protein. Bars represent the mean and standard deviation from n = 3 preparations; the absence of a bar represents no detectable expression. Statistically significant differences between Wistar and TR– are indicated (*, P < 0.05).

Fig. 4.
Fig. 4.

Immunohistochemical staining of Mrp4 (arrows) in the duodenum (A), jejunum (B), ileum (C), and colon (D) of wild-type (left-hand column) and TR– (right-hand column) rats. Slides were counterstained with hematoxylin and eosin, and images were taken at 200× magnification. Bar represents 50 μm. Color images are available as Supplemental Data.

Immunohistochemistry. Preliminary immunohistochemical localization of Mrp4 was conducted because this is the first study to detect Mrp4 protein in the rat intestine. Results of immunohistochemical staining of Mrp4 in the intestine are shown in Fig. 4. Positive staining for Mrp4 in the small intestine appeared to be confined to the cytoplasm of enterocytes at the tips of villi. The staining was somewhat stronger in the basal portion of the cells, and individual strongly positive cells in the crypts appear to be neuroendocrine cells. No differences in staining patterns were apparent between small intestinal samples from wild-type and TR– rats. Positive staining in the colon was confined strictly to the surface epithelium with no staining in the glands. The colon sample from the wild-type rat showed strong staining of surface epithelium, whereas the TR– sample had faint staining that was of similar intensity to the smooth muscle artifactual staining; however, Western blot analysis from three separate rats suggested that the expression of Mrp4 in the colon was similar between wild-type and TR– rats.

Discussion

Mrp2-deficient rats (TR– and EHBR) and their transport-competent counterparts serve as useful models to study the effects of Mrp2 on drug disposition, and provide a rodent model for human Dubin-Johnson syndrome (Dubin and Johnson, 1954; Jansen et al., 1985). However, several other important biochemical differences exist between the mutant and wild-type rats that must be considered, and the current study was designed to characterize the differences in protein expression of several key transport proteins and UGT1a in multiple tissues from Wistar transport-competent and Mrp2-deficent (TR–) rats using semiquantitative Western blot analysis.

As reported previously (Hirohashi et al., 1998; Ogawa et al., 2000; Akita et al., 2001), Mrp3 is significantly up-regulated in the liver of EHBR and TR– rats. The current studies confirm these findings; a significant (∼6-fold) increase in Mrp3 protein expression was observed in TR– relative to wild-type rats. Ntcp expression was decreased by 60% in TR– rat livers, suggesting a compensatory mechanism to reduce already elevated hepatocyte bile acid concentrations (Jansen et al., 1985; Trauner and Boyer, 2003). Oatp1a1 and Oatp1a4 were not significantly altered in TR– rats compared with Wistar controls, similar to a previous study in EHBRs (Akita et al., 2001). The similar expression of these Oatps in control and TR– rats may be related to the vital function that these promiscuous transporters play in the hepatic uptake of a variety of endogenous and exogenous compounds (Kim, 2003). These observations, however, are not consistent with a recent report demonstrating an ∼50% reduction in Oatp1a1 and Oatp1a4 protein expression in livers from EHBRs compared with Sprague-Dawley controls (Kuroda et al., 2004). Possible reasons for this discrepancy between the current and previous studies in EHBR rats are not known (Akita et al., 2001).

Expression of the UGT1a family of drug-conjugating enzymes [detected with a cross-reactive human UGT1A family antibody (Kessler et al., 2002)] was significantly up-regulated in TR– rats (∼3.5-fold). Although previous studies have demonstrated that an apparent functional increase in bilirubin glucuronidation is evident in EHBRs (Ohmori et al., 1991), other reports suggested similar UGT activity between wild-type and TR– rat livers (Jäger et al., 1997). No direct evidence for an increase in UGTs at the protein level has been described prior to the findings presented here. Recently it was shown that Mrp3 and members of the UGT family were both inducible by 1,7-phenanthroline (Wang et al., 2003); however, UGT1a1, the predominant member of the UGT1a family expressed in the liver (Shelby et al., 2003), was not significantly induced.

Up-regulation of both Mrp3 and UGT1a in the liver of TR– rats may result from the activation of a common nuclear hormone receptor, such as the farnesoid X receptor, pregnane X receptor, or constitutive androstane receptor (Schuetz et al., 2001; Chen et al., 2003b; Guo et al., 2003; Zollner et al., 2003). This may provide a coordinated mechanism to glucuronidate and transport potential toxicants out of the hepatocyte for renal excretion. The concomitant increase in UGT1a expression observed in the kidney of TR– rats is consistent with this hypothesis. However, further investigation is required before the increase in basolateral Mrp3 expression in the kidney (Figs. 1 and 2) can be incorporated into this hypothesis.

No significant differences in transport protein expression were found in whole-brain homogenates from Wistar and TR– rats (Fig. 2C). Expression of Oatp1a1 and Oatp1a4 in the brain are consistent with previous reports (Angeletti et al., 1997; Gao et al., 1999; Rausch-Derra et al., 2001). Whether Mrp2 is expressed in rat brain still remains somewhat controversial, with mRNA expression and some functional evidence demonstrating the presence of Mrp2 at the level of the blood-brain barrier in rats (Miller et al., 2000; Potschka et al., 2003). Although mRNA and Western blot analysis of bovine brain microvessel endothelial cells did not confirm these findings (Zhang et al., 2000), this may reflect species differences or culturing effects. In the current study, only a weak signal at the molecular weight of Mrp2 was detected in samples from both wild-type and TR– rat brain, suggesting that this band may be the result of nonspecific binding to other cellular constituents (data not shown). Thus, expression of Mrp2 protein in the rat brain was not confirmed.

Interestingly, Mrp3 expression in the small intestine of TR– rats was significantly decreased compared with wild type; however, expression in the colon was similar. In contrast, expression of UGT1a enzymes was similar in the intestine of TR– and wild-type rats, suggesting that mechanisms governing hepatic, renal, and intestinal expression of Mrp3 and UGT1a may not be coordinately regulated. The lack of coordinate regulation of Mrp3 and UGT1a between these organs is similar to that of hepatic and intestinal P-gp and CYP 3A expression (Lown et al., 1994; Paine et al., 1997; Brady et al., 2002). Relatively high expression of both Mrp3 and Mrp4 was evident in the colon and may suggest a physiological role for these transport proteins in this tissue. The down-regulation of basolateral Mrp3 expression in the small intestine of TR– rats appears to be consistent with the TR– phenotype, such that intestinal (re)uptake of organic anions, including conjugated bile salts, would be attenuated. Intestinal expression of Mrp4 mRNA previously was demonstrated (Chen and Klaassen, 2004). However, the current study is the first to detect Mrp4 protein by Western blot; therefore, preliminary cellular localization studies of Mrp4 in the intestine were conducted. Immunohistochemical staining (Fig. 4) demonstrated that Mrp4 was localized primarily to the basal cytoplasmic region of enterocytes at the tips of villi. Although the staining pattern of Mrp4 was not distinctly localized to the basolateral membrane as previously observed in the liver (Assem et al., 2004), Mrp4 may still have a role in the basolateral membrane transport of sulfate-conjugated bile salts and nucleotides (Schuetz et al., 2001; Sampath et al., 2002).

In summary, several important differences in transport protein and UGT1a enzyme expression were evident in Mrp2-deficient TR– rats compared with transport-competent Wistar controls when examined using the semiquantitative Western blot technique. Also, important tissue-specific differences in protein expression were noted along with regional differences in protein expression in the gastrointestinal tract. Mrp3 was significantly up-regulated in the liver and kidney of TR– rats compared with Wistar controls as described previously, but was down-regulated in the small intestine. Expression of Mrp4 was unchanged in the liver, kidney, brain, and intestine of TR– rats. Interestingly, members of the UGT1a family were up-regulated in the liver and kidney of TR– rats but were unchanged in the intestine. Taken together, the alterations in Mrp3 and UGT1a expression in TR– rats may reflect a coordinated mechanism to aid in the elimination of compounds through glucuronidation and renal excretion. It is clear that in knockout models, such as the TR– rat, numerous adaptive changes in protein expression occur. These changes can significantly confound interpretation of pharmacokinetic and drug disposition data, and in the case of the TR– rat, differences in drug disposition may not be ascribed solely to Mrp2 deficiency. Clearly, hepatic, renal, and intestinal alterations in expression of other proteins, particularly Mrp3 and UGT1a, compensate for loss of Mrp2 function.

Note Added in Proof. While the manuscript was undergoing review, Chen et al. (2005) published results demonstrating a 200% increase in Mrp4 protein expression in the kidney of TR– rats compared with wild-type controls. Based on experiments conducted in our laboratory, the polyclonal Mrp4 antibody detailed by Leggas et al. (2004) provided results similar to those of a commercially available monoclonal antibody to MRP4 (M4I-10; Alexis Biochemicals, San Diego, CA). Our laboratory then repeated Mrp4 Western blot experiments in kidney tissue of TR– and wild-type rats (n = 3 per group) using the polyclonal Mrp4 antibody detailed by Leggas et al. (2004). Mrp4 protein expression in TR– rats was slightly higher than that observed in wild-type controls; however, expression levels were not statistically different when normalized for β-actin. The apparent discrepancy in these results may be due to differences in experimental methodology and/or housing/dietary factors.

Acknowledgments

We gratefully acknowledge Drs. Peter Meier, Bruno Stieger, Yuichi Sugiyama, and Paul Dawson for the generous contribution of primary antibodies, and Robert Schoonhaven (Department of Environmental Health, Molecular Carcinogenesis and Disease Susceptibility, University of North Carolina at Chapel Hill) and Dr. Virginia Godfrey (Veterinary Pathology, University of North Carolina at Chapel Hill) for assistance with the immunohistochemical analysis and interpretation.

Footnotes

  • This work was supported by National Institutes of Health Grants GM41935, GM60904, ES058571, and CA23099; by Cancer Center Support Grant P30 CA21745; and by the American Lebanese Syrian Associated Charities. B.M.J. is supported by a University of North Carolina Clinical Pharmacokinetics/Pharmacodynamics fellowship in collaboration with GlaxoSmithKline (Research Triangle Park, NC). The results of this study have been presented in part at the American Association of Pharmaceutical Scientists Annual Meetings in 2003 (Oct 26–30; Salt Lake City, UT) and 2004 (2004 Nov 7–10; Baltimore, MD).

  • Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.

  • doi:10.1124/dmd.105.005793.

  • ABBREVIATIONS: Mrp, multidrug resistance-associated protein; TR–, transport-deficient; EHBR, Eisai hyperbilirubinemic rats; P450, cytochrome P450; Oatp, organic anion transporting polypeptide; P-gp, P-glycoprotein; BCRP, breast cancer resistance protein; Ntcp, sodium-dependent taurocholate cotransporting polypeptide; Bsep, bile salt export pump; TBS-T, Tris-buffered saline with Tween 20; Ibat, ileal bile acid transporter; PMSF, phenylmethanesulfonyl fluoride; UGT, UDP-glucuronosyl transferase; bis-Tris, 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)-propane-1,3-diol.

  • ↵ Embedded Image The online version of this article (available at http://dmd.aspetjournals.org) contains supplemental material.

    • Received May 30, 2005.
    • Accepted September 28, 2005.

References

  1. ↵
    Akita H, Suzuki H, and Sugiyama Y (2001) Sinusoidal efflux of taurocholate is enhanced in Mrp2-deficient rat liver. Pharm Res (NY) 18: 1119–1125.
    OpenUrl
  2. ↵
    Angeletti RH, Novikoff PM, Juvvadi SR, Fritschy JM, Meier PJ, and Wolkoff AW (1997) The choroid plexus epithelium is the site of the organic anion transport protein in the brain. Proc Natl Acad Sci USA 94: 283–286.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Assem M, Schuetz EG, Leggas M, Sun D, Yasuda K, Reid G, Zelcer N, Adachi M, Strom S, Evans RM, et al. (2004) Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J Biol Chem 279: 22250–22257.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Borst P, Evers R, Kool M, and Wijnholds J (1999) The multidrug resistance protein family. Biochim Biophys Acta 1461: 347–357.
    OpenUrlPubMed
  5. ↵
    Brady JM, Cherrington NJ, Hartley DP, Buist SC, Li N, and Klaassen CD (2002) Tissue distribution and chemical induction of multiple drug resistance genes in rats. Drug Metab Dispos 30: 838–844.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Chan LMS, Lowes S, and Hirst BH (2004) The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 21: 25–51.
    OpenUrlCrossRefPubMed
  7. ↵
    Chandra P and Brouwer KLR (2004) The complexities of hepatic drug transport: Current knowledge and emerging concepts. Pharm Res (NY) 21: 719–735.
    OpenUrl
  8. ↵
    Chen C, Hennig GE, and Manautou JE (2003a) Hepatobiliary excretion of acetaminophen glutathione conjugate and its derivatives in transport-deficient (TR–) hyperbilirubinemic rats. Drug Metab Dispos 31: 798–804.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Chen C and Klaassen CD (2004) Rat multidrug resistance protein 4 (Mrp4, Abcc4): molecular cloning, organ distribution, postnatal renal expression and chemical inducibility. Biochem Biophys Res Commun 317: 46–53.
    OpenUrlCrossRefPubMed
  10. ↵
    Chen C, Slitt AL, Dieter MZ, Tanaka Y, Scheffer GL, and Klaassen CD (2005) Up-regulation of Mrp4 expression in kidney of Mrp2-defcient TR– rats. Biochem Pharmacol 70: 1088–1095.
    OpenUrlCrossRefPubMed
  11. ↵
    Chen C, Staudinger JL, and Klaassen CD (2003b) Nuclear receptor, pregnane X receptor, is required for induction of UDP-glucuronosyltransferases in mouse liver by pregnenolone-16 alpha-carbonitrile. Drug Metab Dispos 31: 908–915.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Dietrich CG, De Waart DR, Ottenhoff R, Schoots IG, and Oude Elferink RP (2001) Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in MRP2-deficient rats. Mol Pharmacol 59: 974–980.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Dubin IN and Johnson FB (1954) Chronic idiopathic jaundice with unidentified pigment in liver cells. Medicine 33: 155–179.
    OpenUrlPubMed
  14. ↵
    Gao B, Stieger B, Noé B, Fritschy JM, and Meier PJ (1999) Localization of the organic anion transporting polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain. J Histochem Cytochem 47: 1255–1264.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Guo GL, Lambert G, Negishi M, Ward JM, Brewer HB Jr, Kliewer SA, Gonzalez FJ, and Sinal CJ (2003) Complementary roles of farnesoid X receptor, pregnane X receptor and constitutive androstane receptor in protection against bile acid toxicity. J Biol Chem 278: 45062–45071.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Hirohashi T, Suzuki H, Ito K, Ogawa K, Kume K, Shimizu T, and Sugiyama Y (1998) Hepatic expression of multidrug resistance-associated protein-like proteins maintained in eisai hyperbilirubinemic rats. Mol Pharmacol 53: 1068–1075.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Hori S, Ohtsuki S, Tachikawa M, Kimura N, Kondo T, Watanabe M, Nakashima E, and Terasaki T (2004) Functional expression of rat ABCG2 on the luminal side of brain capillaries and its enhancement by astrocyte-derived soluble factor(s). J Neurochem 90: 526–536.
    OpenUrlCrossRefPubMed
  18. ↵
    Jäger W, Sartori M, Herzog W, and Thalhammer T (1998) Genistein metabolism in liver microsomes of Wistar and mutant TR– rats. Res Commun Mol Pathol Pharmacol 100: 105–116.
    OpenUrlPubMed
  19. ↵
    Jäger W, Winter O, Halper B, Salamon A, Sartori M, Gajdzik L, Hamilton G, Theyer G, Graf J, and Thalhammer T (1997) Modulation of liver canalicular transport processes by the tyrosine-kinase inhibitor genistein: implications of genistein metabolism in the rat. Hepatology 26: 1467–1476.
    OpenUrlCrossRefPubMed
  20. ↵
    Jansen PL, Peters WH, and Lamers WH (1985) Hereditary chronic conjugated hyperbilirubinemia in mutant rats caused by defective hepatic anion transport. Hepatology 5: 573–579.
    OpenUrlCrossRefPubMed
  21. ↵
    Kartenbeck J, Leuschner U, Mayer R, and Keppler D (1996) Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. Hepatology 23: 1061–1066.
    OpenUrlPubMed
  22. ↵
    Kessler FK, Kessler MR, Auyeung DJ, and Ritter JK (2002) Glucuronidation of acetaminophen catalyzed by multiple rat phenol UDP-glucuronosyltransferases. Drug Metab Dispos 30: 324–330.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Kim RB (2003) Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur J Clin Investig 33: 1–5.
    OpenUrlPubMed
  24. ↵
    König J, Rost D, Cui Y, and Keppler D (1999) Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology 29: 1156–1163.
    OpenUrlCrossRefPubMed
  25. ↵
    Kuroda M, Kobayashi Y, Tanaka Y, Itani T, Mifuji R, Araki J, Kaito M, and Adachi Y (2004) Increased hepatic and renal expressions of multidrug resistance-associated protein 3 in Eisai hyperbilirubinuria rats. J Gastroenterol Hepatol 19: 146–153.
    OpenUrlCrossRefPubMed
  26. ↵
    Kushura H and Sugiyama Y (2004) Efflux transport systems for organic anions and cations at the blood-CSF barrier. Adv Drug Delivery Rev 56: 1741–1763.
    OpenUrlCrossRefPubMed
  27. ↵
    Lee W and Kim RB (2004) Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol 44: 137–166.
    OpenUrlCrossRefPubMed
  28. ↵
    Leggas M, Adachi M, Scheffer GL, Sun D, Wielinga P, Du G, Mercer KE, Zhuang Y, Panetta JC, Johnston B, et al. (2004) Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol 24: 7612–7621.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Leslie EM, Deeley RG, and Cole SPC (2005) Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2 and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204: 216–237.
    OpenUrlCrossRefPubMed
  30. ↵
    Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, and Watkins PB (1994) Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 22: 947–955.
    OpenUrlAbstract
  31. ↵
    Miller DS, Nobmann SN, Gutmann H, Toeroek M, Drewe J, and Fricker G (2000) Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. Mol Pharmacol 58: 1357–1367.
    OpenUrlPubMed
  32. ↵
    Ogawa K, Suzuki H, Hirohashi T, Ishikawa T, Meier PJ, Hirose K, Akizawa T, Yoshioka M, and Sugiyama Y (2000) Characterization of inducible nature of MRP3 in rat liver. Am J Physiol 278: G438–G446.
    OpenUrl
  33. ↵
    Ohmori S, Kuriya S, Uesugi T, Horie T, Sagami F, Mikami T, Kawaguchi A, Rikihisa T, and Kanakubo Y (1991) Decrease in the specific forms of cytochrome P-450 in liver microsomes of a mutant strain of rat with hyperbilirubinuria. Res Commun Chem Pathol Pharmacol 72: 243–253.
    OpenUrlPubMed
  34. ↵
    Ortiz DF, Li S, Iyer R, Zhang X, Novikoff P, and Arias IM (1999) MRP3, a new ATP-binding cassette protein localized to the canalicular domain of the hepatocyte. Am J Physiol 276: G1493–G1500.
    OpenUrlPubMed
  35. ↵
    Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, and Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283: 1552–1562.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    Paulusma CC, Bosma PJ, Zaman GJ, Bakker CT, Otter M, Scheffer GL, Scheper RJ, Borst P, and Oude Elferink RP (1996) Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science (Wash DC) 271: 1126–1128.
    OpenUrlAbstract
  37. ↵
    Potschka H, Fedrowitz M, and Löscher W (2003) Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther 306: 124–131.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    Rausch-Derra LC, Hartley DP, Meier PJ, and Klaassen CD (2001) Differential effects of microsomal enzyme-inducing chemicals on the hepatic expression of rat organic anion transporters, OATP1 and OATP2. Hepatology 33: 1469–1478.
    OpenUrlCrossRefPubMed
  39. ↵
    Sampath J, Adachi M, Hatse S, Naesens L, Balzarini J, Flatley RM, Matherly LH, and Schuetz JD (2002) Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci 4: E14.
    OpenUrlCrossRefPubMed
  40. ↵
    Schuetz EG, Strom S, Yasuda K, Lecureur V, Assem M, Brimer C, Lamba J, Kim RB, Ramachandran V, Komoroski BJ, et al. (2001) Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters and cytochrome P450. J Biol Chem 276: 39411–39418.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    Shelby MK, Cherrington NJ, Vansell NR, and Klaassen CD (2003) Tissue mRNA expression of the rat UDP-glucuronosyltransferase gene family. Drug Metab Dispos 31: 326–333.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    Trauner M and Boyer JL (2003) Bile salt transporters: molecular characterization, function and regulation. Physiol Rev 83: 633–671.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    Wang S, Hartley DP, Ciccotto SL, Vincent SH, Franklin RB, and Kim MS (2003) Induction of hepatic phase II drug-metabolizing enzymes by 1,7-phenanthroline in rats is accompanied by induction of MRP3. Drug Metab Dispos 31: 773–775.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Xiong H, Suzuki H, Sugiyama Y, Meier PJ, Pollack GM, and Brouwer KLR (2002) Mechanisms of impaired biliary excretion of acetaminophen glucuronide after acute phenobarbital treatment or phenobarbital pretreatment. Drug Metab Dispos 30: 962–969.
    OpenUrlAbstract/FREE Full Text
  45. ↵
    Zhang Y, Han H, Elmquist WF, and Miller DW (2000) Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells. Brain Res 876: 148–153.
    OpenUrlCrossRefPubMed
  46. ↵
    Zollner G, Fickert P, Fuchsbichler A, Silbert D, Wagner M, Arbeiter S, Gonzalez FJ, Marschall HU, Zatloukal K, Denk H, and Trauner M (2003) Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. J Hepatol 39: 480–488.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleArticle

CHARACTERIZATION OF TRANSPORT PROTEIN EXPRESSION IN MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN (MRP) 2-DEFICIENT RATS

Brendan M. Johnson, Peijin Zhang, John D. Schuetz and Kim L. R. Brouwer
Drug Metabolism and Disposition April 1, 2006, 34 (4) 556-562; DOI: https://doi.org/10.1124/dmd.105.005793
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement